Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity
in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend
Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian
cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
People's Hospital of Quzhou Qilu Hospital of Shandong University Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.